TB-500 — Thymosin β-4 (1-4) Synthetic Fragment

Discovery and Characterisation

Thymosin β-4 (Tβ4) was first isolated and characterised at George Washington University in the early 1980s by Allan Goldstein and colleagues while investigating the immunological role of thymic peptides. The parent molecule is a 43-amino-acid polypeptide with a molecular weight of approximately 4,961 Da, widely distributed across mammalian tissues and remarkably conserved across species — an early indicator of its fundamental biological importance.

The commercially circulated compound known as TB-500 is not the full 43-residue Thymosin β-4 molecule. It refers specifically to a synthetic 7-amino-acid active fragment: Ac-Lys-Lys-Thr-Glu-Thr-Gln (acetylated at the N-terminus, commonly written Ac-LKKTETQ). This fragment corresponds to positions 17–23 of the parent sequence and was characterised through structure-activity studies in the 1990s as the minimal actin-binding motif responsible for most of Tβ4's biological effects.

This distinction matters clinically and analytically. A vial labelled "TB-500" at 5 mg contains a substance with a molecular weight of ~889 Da — not the 4,961 Da full peptide. Vendors who label full Thymosin β-4 as TB-500, or vice versa, are using imprecise terminology. Research protocols should specify which entity is under investigation.

The Goldstein lab published extensively on Tβ4's actin-sequestering activity throughout the 1980s and 1990s, and interest in its tissue-repair properties accelerated dramatically after Bock-Marquette et al. demonstrated cardiac regenerative activity in 2004. The TB-500 fragment has since become the predominant form studied in animal models because of its simpler synthesis, lower cost, and comparable activity profile at the primary actin-binding domain. A recent review by the original Bock-Marquette group situates Tβ4 within emerging anti-ageing regenerative-medicine strategies (Bock-Marquette 2023, PMID 36709593).

---

Mechanism of Action

TB-500's primary biochemical action is G-actin sequestration. The peptide binds monomeric (globular) actin in a 1:1 stoichiometric ratio, modulating the equilibrium between G-actin and filamentous (F-actin) within cells. By buffering the local pool of free G-actin, TB-500 influences cell motility, shape, and the ability of cells — particularly endothelial cells and myoblasts — to migrate into sites of injury. Bubb's structural review of Tβ4's actin-binding interactions established the biochemical basis for this sequestering activity (Bubb 2003, PMID 12852258).

Beyond actin dynamics, several downstream signalling pathways are implicated:

KLF4 and miR-146a upregulation. In cardiac and endothelial models, Tβ4 and its active fragment upregulate Krüppel-like factor 4 (KLF4), a transcription factor linked to endothelial cell identity and anti-inflammatory signalling. Concurrent upregulation of microRNA miR-146a attenuates NF-κB-driven inflammation and blunts pro-inflammatory cytokine cascades.

Angiogenic growth factor recruitment. TB-500 promotes the expression and secretion of vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and hepatocyte growth factor (HGF). This triad drives neovascularisation — the formation of new capillary networks — and is central to the peptide's observed effects in wound repair and ischaemic tissue models.

M2 macrophage polarisation. Emerging evidence from in vitro studies suggests Tβ4 shifts macrophage phenotype toward the anti-inflammatory M2 state, reducing TNF-α and IL-1β secretion and increasing IL-10 and TGF-β. This mechanism partially overlaps with, but is mechanistically distinct from, BPC-157's COX-2/NO pathway activity. A related review examined Tβ4's regulation of actin dynamics in the context of sepsis-associated immune dysfunction, a setting where this anti-inflammatory shift is directly relevant (Belsky 2018, PMID 29508629).

Epicardial progenitor mobilisation. Smart et al. demonstrated that Tβ4 could reactivate dormant epicardial progenitor cells in the adult mouse heart, stimulating their migration into infarcted myocardium and differentiating into smooth muscle and endothelial lineages [PMID: 17108969]. This finding positioned Tβ4 as one of the few peptides with credible preclinical evidence for true cardiac regeneration rather than mere scar remodelling.

TB-500's long tissue partitioning — measured in days rather than the minutes typical of unmodified peptides — is a distinguishing PK feature relative to most other research peptides. See our peptide half-life visualiser for how this decay curve compares to BPC-157 and other tissue-repair peptides.

---

Researched Applications

Tendon and Musculoskeletal Repair

Preclinical models have explored Tβ4 and its active fragment in Achilles tendon injury. Related work by Chang et al. with structurally analogous repair peptides demonstrated enhanced fibroblast proliferation and upregulated growth-factor receptor expression in tendon tissue. Rodent models of Achilles transection showed accelerated histological recovery and improved tensile strength metrics in treated animals compared to controls, though direct high-quality TB-500-specific tendon data remains limited to animal studies.

Cardiac Infarction

The landmark study by Bock-Marquette et al. in Nature (2004) showed that systemic administration of Thymosin β-4 in mice following experimental myocardial infarction activated integrin-linked kinase (ILK), promoted cardiomyocyte survival, reduced infarct size, and improved ventricular function. Smart et al. extended this in a 2007 Nature paper, demonstrating that Tβ4 primed epicardial progenitor cells for post-injury mobilisation [PMID: 17108969]. These results have generated sustained interest in cardiac indications, although no human trials have yet completed with TB-500 specifically. A broader review of Tβ4-mediated cardioprotection situates these findings within the wider cardiac-repair literature (Pipes 2016, PMID 27450736).

Corneal and Ocular Wound Healing

Gabriel Sosne's group at Wayne State University has published extensively on Tβ4 in ophthalmological contexts. Sosne et al. defined short peptide sequences — including the LKKTETQ motif — as sufficient to recapitulate Tβ4's anti-inflammatory and wound-healing effects on corneal epithelium. Dry eye, corneal ulceration, and chemical injury models in rabbits showed accelerated re-epithelialisation and reduced stromal scarring. RegeneRx Biopharmaceuticals ran a Phase II trial (RGN-259 eye drops) based on this work; results suggested tolerability but no Phase III has been completed. Sosne has separately reviewed the bench-to-bedside development of Tβ4 in ophthalmology (Sosne 2018, PMID 30063853).

Renal Biomarker Research

Maar et al. identified urinary Thymosin β-4 as a candidate biomarker for tubular injury in kidney disease, suggesting endogenous upregulation of the peptide in response to nephrotoxic insult. This line of research reinforces the concept that Tβ4 is a stress-responsive repair signal rather than a constitutive growth factor. A more recent review has proposed Tβ4 as an emerging therapeutic candidate — rather than only a biomarker — in kidney disease (Di 2026, PMID 41570941).

---

Dosing Range (Preclinical Research Context)

The following parameters are derived exclusively from published animal studies and anecdotal research community reports. They have not been validated in controlled human trials and are provided for educational and research-design purposes only.

Loading phase (weeks 1–4): 2.0–2.5 mg administered subcutaneously (SC) or intramuscularly (IM) twice weekly.

Maintenance phase (weeks 5 onward): 2.0 mg once weekly SC or IM.

Cycle length: Research protocols typically span 4–8 weeks. Extended use beyond this window has not been systematically evaluated for safety in any published human study.

Injection site: Subcutaneous administration at sites distal to the target tissue is the most common approach in rodent models; proximity targeting (peri-lesional injection) has also been employed in some equine veterinary contexts.

TB-500 is often co-administered with BPC-157 in preclinical repair models, leveraging complementary mechanisms — TB-500's actin-modulating and angiogenic effects alongside BPC-157's NO/COX-2 pathway activity. Whether synergy exists at the clinical level is unknown.

The parameters above are extrapolated from rodent and equine research. Rodent-to-human dose scaling is not a simple mg/kg conversion — see our species-dose-scaling explainer for the FDA HED framework underlying this kind of translation.

---

Safety Profile

In preclinical rodent and equine models, Thymosin β-4 and the TB-500 fragment have demonstrated a consistently benign short-term tolerability profile. No dose-limiting toxicities have been reported in published animal studies at the doses described above.

The primary theoretical safety concern is the peptide's pro-angiogenic activity. VEGF and FGF upregulation is advantageous in ischaemic or injured tissue but could theoretically support angiogenesis in occult neoplastic lesions. No causal link between TB-500 administration and tumour development has been established in peer-reviewed literature, but the mechanistic plausibility warrants caution, particularly in subjects with personal or family history of malignancy.

Other considerations include:

• Injection-site reactions: Transient localised erythema or mild discomfort; generally self-resolving.
• Immunological effects: The M2-polarising activity could theoretically modulate immune surveillance, though this has not been characterised in the context of chronic administration.
• Absence of long-term data: No multi-year safety datasets exist for TB-500 in any species. Extrapolation of short-term rodent tolerability to humans requires significant caution.

---

UK Regulatory Status

TB-500 is not approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for any therapeutic indication in humans or animals. It is not licensed as a veterinary medicine under the Veterinary Medicines Directorate (VMD) framework.

In the United Kingdom, TB-500 occupies an ambiguous legal space: it is not a controlled substance under the Misuse of Drugs Act 1971, nor is it explicitly prohibited for purchase. However, administration to a human being would constitute supply or administration of an unlicensed medicinal product under the Human Medicines Regulations 2012, which is a criminal offence when conducted outside an appropriate research exemption.

Import for personal use is unregulated in law but is not sanctioned by the MHRA and may attract customs scrutiny. Any legitimate use of TB-500 in the United Kingdom must occur within the framework of a registered clinical trial (MHRA Clinical Trials Authorisation) or as part of a formal in vitro or ex vivo laboratory research programme. This monograph is provided for educational purposes only and does not constitute medical advice or an endorsement of human use.

---

Reconstitution Guide

TB-500 (the 7-aa fragment at 889 Da) is somewhat less hydrophilic than BPC-157 and benefits from a slightly more deliberate reconstitution approach.

Recommended reconstitution concentration: 2 mg/mL using bacteriostatic water (0.9% benzyl alcohol) to permit multi-dose use.

Step-by-step protocol:

1. Allow the lyophilised vial to equilibrate to room temperature for 10–15 minutes before opening to minimise condensation.
2. Wipe the vial stopper with an alcohol swab and allow to dry.
3. Draw bacteriostatic water into an insulin syringe — for a 5 mg vial, draw 2.5 mL to achieve a 2 mg/mL concentration.
4. Insert the needle at an angle and allow the water to run slowly down the glass wall of the vial. Do not inject directly onto the lyophilised cake — this shears the peptide.
5. Gently swirl (do not vortex or shake) until the cake dissolves completely. TB-500 may take 60–90 seconds to dissolve fully; a slightly cloudy intermediate stage is normal and resolves with continued gentle agitation.
6. At 2 mg/mL, each 0.1 mL (10 units on an insulin syringe) delivers 0.2 mg. A 2.0 mg dose = 1.0 mL; a 2.5 mg dose = 1.25 mL.

Storage: Unreconstituted vials should be stored at 4 °C (refrigerated) and away from light. Reconstituted solution should be refrigerated and used within 28 days. Do not freeze reconstituted peptide.

---

Frequently Asked Questions

Is TB-500 the same as Thymosin β-4? No. TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) corresponding to the actin-binding region of the full 43-residue Thymosin β-4 peptide. The molecular weights differ substantially: ~889 Da versus ~4,961 Da. Some vendors use the names interchangeably, which is chemically inaccurate. Researchers should verify which entity they are working with.

How does TB-500 differ from BPC-157? BPC-157 is a 15-residue synthetic fragment of a body protection compound isolated from gastric juice; TB-500 is a fragment of a thymic peptide. Their mechanisms partially overlap (both modulate angiogenesis and promote tissue repair) but operate through distinct primary pathways. BPC-157 acts principally via NO synthase and COX-2 pathways; TB-500 acts principally through G-actin sequestration and KLF4/VEGF upregulation. They are frequently co-researched for hypothesised complementary action.

What is the theoretical basis for the <2 mg/mL solubility recommendation? Above approximately 2 mg/mL, the LKKTETQ fragment begins to show concentration-dependent aggregation in aqueous solution in some preparations. Reconstituting at 2 mg/mL provides an acceptable balance between injectate volume and peptide stability. Higher concentrations (<5 mg/mL) can be achieved with dilute acetic acid (0.1–0.5%) as a reconstitution vehicle if smaller injection volumes are required for a specific research design.

Is TB-500 detectable in anti-doping screens? Thymosin β-4 and its fragments are included on the WADA Prohibited List under the category of peptide hormones and related substances. High-performance liquid chromatography–mass spectrometry (HPLC-MS/MS) methods capable of detecting sub-nanogram concentrations in urine have been described in the literature. Detection windows are estimated at several days post-administration but have not been formally characterised across human pharmacokinetic studies.

Can TB-500 and BPC-157 be drawn into the same syringe? No incompatibility has been reported in preclinical literature, but co-administration in a single injection has not been formally validated. Most research protocols administer them separately to preserve precise dosing control and to attribute any observed effects to individual compounds.

---

TB-500 appears in these research stacks:

• BPC-157 + TB-500 Healing Stack
• BPC-157 + TB-500 + GHK-Cu Advanced Recovery
• GHK-Cu + TB-500 Skin Stack
• TB-500 + BPC-157 Tendon Repair Stack

Related on this site

• BPC-157 vs TB-500 — evidence comparison
• Angiogenesis & VEGFR2 mechanism map
• Wound healing phase mechanism map
• G-actin sequestration (glossary)
• Time-dependent repair cascade
• BPC-157 + TB-500 — combination evidence review
• TB-500 + BPC-157 tendon-repair review

Regulatory and clinical status

UK status: Unapproved research compound in UK, US, EU. Laboratory and in vitro research use only.

Read more about how UK regulation applies to peptides in our UK regulation hub and our explanation of what “research use only” means in the UK. PeptideStacks does not make editorial sourcing recommendations within research content; any vendor links elsewhere on this page appear in a clearly-labelled sponsor block (see our conflict-of-interest disclosure).

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

1. Bock-Marquette I, Maar K, Maar S, et al.. Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. International Immunopharmacology. 2023;116 :109741 doi:10.1016/j.intimp.2023.109741 · PMID: 36709593
2. Bubb MR. Thymosin beta 4 interactions. Vitamins and Hormones. 2003;66 :297-316 doi:10.1016/s0083-6729(03)01008-2 · PMID: 12852258
3. Belsky JB, Rivers EP, Filbin MR, et al.. Thymosin beta 4 regulation of actin in sepsis. Expert Opinion on Biological Therapy. 2018;18 :193-197 doi:10.1080/14712598.2018.1448381 · PMID: 29508629
4. Di H, Huang J, Zhang D, et al.. Thymosin beta 4: An emerging therapeutic candidate for kidney diseases. Peptides. 2026;195 :171467 doi:10.1016/j.peptides.2026.171467 · PMID: 41570941
5. Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opinion on Biological Therapy. 2018;18 :99-104 doi:10.1080/14712598.2018.1486818 · PMID: 30063853
6. Pipes GT, Yang J. Cardioprotection by Thymosin Beta 4. Vitamins and Hormones. 2016;102 :209-26 doi:10.1016/bs.vh.2016.04.004 · PMID: 27450736

Published: 2026-08-28Last updated: 2026-08-28Last reviewed: 2026-08-28

Pages on PeptideStacks are reviewed when relevant new evidence becomes available. If you spot an error or have new evidence to suggest, please use our corrections policy.